Bivatuzumab

未知生产厂商

Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6.

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6.

Investigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer.

技术标识符

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

未检索到以该名称命名的专利

专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。